SynthesisBMJ open gastroenterology2025
Parasitic colitis misdiagnosis as inflammatory bowel disease in high-income settings and association with poor clinical outcomes when exposed to corticosteroids: a systematic review of case reports.
Synthesis in BMJ open gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Fulminant disseminated strongyloidiasis mimicking inflammatory bowel disease: a case report.Future science OA · 2026Article
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Colonic Strongyloides stercoralis With Multimodality Imaging, Endoscopic, and Histopathologic Correlation.Cureus · 2026Article
- Case Report: From chronic infection to disseminated strongyloidiasis: a case of corticosteroid-induced hyperinfection syndrome.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesParasitic colitis is highly prevalent worldwide, may mimic inflammatory bowel disease (IBD) and is encountered by non-specialist physicians in high-income, non-endemic settings. In this context, patients may be at risk of misdiagnosis and poor outcomes. However, cases are not routinely reported, limiting the evidence base to individual case reports. We aimed to systematically describe and evaluate the diagnosis, clinical course and outcomes of affected patients whose cases have been reported in high-income settings.
designA systematic review of the literature using the Preferred Reporting Items for Systematic Reviews and Meta-analyses framework. DATA SOURCES: PubMed and Scopus databases were searched for publications from between 1 January 2012 and 10 January 2025. ELIGIBILITY CRITERIA: Case reports of undifferentiated colitis presenting in high-income settings, where the aetiological agent was ultimately found to be parasitological, were eligible for inclusion. Key exclusion criteria included a history of travel to an endemic area within 4 weeks of presentation. No language restrictions were applied. DATA EXTRACTION AND SYNTHESIS: Key components of each case report, encompassing patient presentation, diagnosis and management, were standardised as categorical descriptors. Key themes were identified, and a thematic synthesis approach was employed.
results52 articles, describing 54 patients, were included in the final analysis: 33 cases of amoebiasis, 15 cases of strongyloidiasis and 6 cases of schistosomiasis. Misdiagnosis occurred in 37 out of 54 patients (69%), with 28 out of 37 (76%) of these misdiagnosed as IBD. Substantial harm was reported in 31 out of 54 (57%) patients, including death in seven patients. Major morbidity (defined as strongyloides hyperinfection syndrome, fulminant amoebic colitis, emergency surgery or sepsis) or death was associated with administration of corticosteroids in cases of strongyloidiasis and amoebiasis, occurring in 8 out of 9 (89%) and 1 out of 6 (17%) patients with strongyloidiasis who received/did not receive corticosteroids, and 10 out of 13 (77%) and 2 out of 20 (10%) patients with amoebiasis, respectively.
conclusionsParasitic colitis poses a diagnostic challenge in high-income settings. Misdiagnosis as IBD is commonly reported, with poor outcomes related to corticosteroid treatment. Awareness of parasitic colitis aetiologies, at-risk groups and diagnostic tests is essential among generalist clinicians assessing undifferentiated colitis to avoid poor outcomes. PROSPERO REGISTRATION NUMBER: CRD420251033374.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.